



# ANNUAL REPORT

# 2021






## OUR ACHIEVEMENTS

2021 marks the 10th anniversary of the Shake It Up Australia Foundation. In the last decade we are proud of the achievements we have made - \$22 million invested in Australian research which funded 63 research projects across 19 institutes together with our partners at The Michael J. Fox Foundation.

Our Patron, His Excellency General the Honourable David Hurley AC DSC (Retd), Governor-General of the Commonwealth of Australia and Mrs Hurley generously hosted a small celebratory event at Admiralty House in March with the Foundation's major donors to commemorate this important occasion.

Whilst the COVID-19 pandemic created challenges in 2021 for our fundraisers and research organisations, we are proud of the way everyone was able to adapt to ensure that Parkinson's research progressed. We are pleased to share the following highlights from 2021:

- Co-funding of nine new research projects to the value of \$6.725 million with our partners at The Michael J. Fox Foundation.
- The launch of the Catalyst Programme velocity to fast-track research to accelerate the discovery of new drug therapies to slow, stop and cure Parkinson's Disease.
- The introduction of a monthly Virtual Research Forum connecting our Parkinson's community with researchers to learn more about the projects we are funding.



**63** Parkinson's  
Research  
Projects



**19** Australian  
Research  
Institutes



**22** Million  
Dollars  
Invested

# Table of Contents

## INTRODUCTION

- 04 A message from our Patron
- 06 CEO Report
- 08 Vision, Mission & Values
- 09 Catalyst Programme velocity
- 10 About Parkinson's
- 12 The Michael J. Fox Foundation
- 13 Robert A. Pritzker Prize for Leadership in Parkinson's

## RESEARCH

- 14 2021 Funded research projects

## FUNDRAISING

- 23 Bequests
- 24 Pause 4 Parkinson's
- 26 Community Fundraising
- 27 Our Heroes
- 29 Corporate Support
- 30 Get Involved

## OUR PEOPLE

- 31 Ambassadors
- 32 Our Team

## GOVERNANCE

- 33 Our Board
- 34 Financial Summary

*Shake It Up Australia Foundation is grateful to Daily Press for their support in the production of this Annual Report*

# A Message from our Patron The Governor-General of the Commonwealth of Australia, His Excellency General the Honourable David Hurley AC DSC (Retd).

As Patron of the Shake It Up Australia Foundation I am delighted to provide this message in support of its Annual Report, particularly in the Foundation's 10th anniversary year. Congratulations to all involved with the Foundation on this significant milestone.

The Foundation's work has been particularly difficult during the pandemic, yet it has had a successful year. I was pleased to learn that research into Parkinson's was not greatly impacted by the pandemic and that the Foundation has continued to make good progress.

In 2020-21 it assisted the funding of nine new research projects to the value of \$6.725 million; developed 'Catalyst Programme velocity' to fast-track research to accelerate the discovery of new drug therapies to prevent, slow, stop and cure Parkinson's Disease; and introduced a monthly Virtual Research Forum connecting the Parkinson's community with researchers to learn more about the projects the Foundation is funding.

On a personal note, one of the highlights of the year for Linda and me was hosting a reception in honour of the Foundation at Admiralty House in March. It was an uplifting occasion for all in attendance and an opportunity to acknowledge the outstanding achievements of the Foundation over the past 10 years, including the co-funding with The Michael J. Fox Foundation of 63 research projects across 19 Australian institutes to the value of \$22 million.

To the Shake It Up Australia Foundation donors, sponsors, supporters, patients, researchers and research institutes – thank you.

## DAVID HURLEY

HIS EXCELLENCY GENERAL

The Honourable David Hurley AC DSC (Retd)

---



“Clyde could sit back and afford to live a private life and to not get involved and deal with his own issues, but Clyde’s enthusiasm and his purity of motive is contagious.”

**MICHAEL J. FOX**



## MESSAGE FROM

### OUR FOUNDER & CEO

We thought 2020 was a challenging year and then along came Delta! 2021 has been equally challenging for us all but despite this we have managed to continue to fund projects and pivot our research strategy to ensure progress.

This year I was honoured to be appointed as a Member (AM) of the Order of Australia (General Division) in the Australia Day Honours List. This recognition is a reflection of our team and the many people who have supported my vision to do everything possible to fast-track better treatments for people living with Parkinson’s disease.

2021 marked the 10th anniversary of the foundation. When I look back on those 10 years, I could never have imagined the level of community support and research achievements we have made - \$22 million invested in Australian research which funded 63 research projects across 19 institutes together with our partners at The Michael J. Fox Foundation. In that time much has been learnt about Parkinson’s pathology as more funds have been invested in science and researchers have collaborated internationally on their discoveries.

As we edge closer to developing a reliable biomarker for Parkinson’s the focus is shifting now to new drug therapies that have the potential to prevent, slow, stop and cure Parkinson’s. One thing we have learnt from COVID-19 is that new drug therapies do not need to take upwards of 10 years to be tested and approved for commercial use. With this in mind we established the Catalyst Programme velocity (CPv) project in July to fast-track research to accelerate the discovery of new drug therapies to prevent, slow, stop and cure Parkinson’s disease. This project is being led by Michael Katz, Rich Balanson and myself in collaboration with our partners at The Michael J. Fox Foundation and Cure Parkinson’s. This project aims to fast-track new drug therapies into clinical trials in Australia in 2022. You can read more about CPv on page 9.

We are grateful to our major donors who have supported this project and the foundation to date – Michael & Frederique Katz, Rich Balanson & Dawn Talbot, Greig Asbury Foundation, Trawalla Foundation, Besen Family Foundation, Andrew & Anna Permezel, Thea & Hayden Snow, The Sherman Foundation, Tim Sims, Campbell Family and Noel & Sue Holmes.

Once again our Pause 4 Parkinson's campaign was impacted by stay at home orders and many of our community fundraising events were unable to proceed. Our Patron, His Excellency General the Honourable David Hurley AC DSC (Retd), Governor-General of the Commonwealth of Australia and Mrs Hurley, generously hosted a very small event to mark our 10th anniversary and launch our Pause 4 Parkinson's campaign at Admiralty House with our major donors and fundraisers. We were grateful to be able to gather together in such a beautiful setting and enjoy Their Excellency's hospitality. A big thank you to all our Pause 4 Parkinson's sponsors for their support.

I would also like to thank our many community fundraisers who despite repeated lockdowns still found creative and unique ways to raise funds for Shake It Up by taking on their own challenges. You can read more about some of our fundraising heroes later in the report.

COVID-19 made us all think outside the square about how to connect with each other during lockdown which resulted in the launch of a monthly Virtual Research Forum. This series has proved to be very popular as researchers share their study aims and progress with people living with Parkinson's online in a live event enabling scientists and patients to connect with each other. I know our researchers have found this connection as valuable as our Parkinson's community. Thank you to all our researchers for taking time out from their labs to present their studies.

I also extend my heartfelt congratulations to Professor Glenda Halliday, who was awarded the 2021 Robert A. Pritzker Prize for Leadership in Parkinson's Research in October by The Michael J. Fox Foundation in recognition of her dedication and expertise to the field of Parkinson's research. Professor Halliday has dedicated her life's work to Parkinson's research and is highly regarded by the international science community.

Earlier this year I met up with the Monkey Mia boys, a group of great Aussie blokes who take on an outback trek each year to raise funds for Parkinson's research. Noel Passalaqua and Andrew Urquhart both have Parkinson's and together with six of their mates have raised over \$185,000 over the last four years for Shake It Up. I caught up with the crew in Alice Springs earlier this year during their Simpson Desert trip to have a beer and thank them for their fantastic support.

The Sohn Hearts & Minds Conference brings leaders in the investment world together each year to raise funds for Australian medical research. This is a truly innovative concept which recognises the importance of medical research to prevent and treat diseases. We were proud and grateful to be a charity beneficiary of this important event again this year.

From our research investments over the last decade we now have a far better understanding of the complex nature of Parkinson's disease. I know we are edging closer to new drug therapies that will see an improved quality of life for people living with Parkinson's. Thank you to each and every individual and organisation who has joined with me on this journey, to the many Australian researchers working to find a cure and to our Board, Ambassadors and staff. Together we will find the answers.

**CLYDE CAMPBELL AM**  
FOUNDER & CEO - SHAKE IT UP



## OUR VISION, MISSION & VALUES

The Shake It Up Australia Foundation is a not-for-profit organisation established in 2011 and in partnership with The Michael J. Fox Foundation (MJFF) promotes and funds Parkinson's disease research in Australia aimed at better treatments and ultimately a cure.



### VISION

Our vision is a world without Parkinson's.



### MISSION

Our mission is to find better treatments that will prevent, slow and stop the progression of Parkinson's and ultimately lead us to a cure.



### OUR VALUES

- Collaboration
- Integrity
- Commitment
- Innovation
- Respect
- Optimistic

**"I urge you to be challenged and inspired by what you do not know."**

Michael J. Fox



# CATALYST PROGRAMME VELOCITY

Traditionally new drug therapies take upwards of 10 years to be tested and approved but the COVID-19 pandemic has proven this does not need to be the reality. Research companies with high value ideas will spend vast amounts of time and money raising capital for clinical trials and negotiating support which adds years to their research and potential outcomes. So earlier this year Shake It Up developed a new programme to fast-track research to accelerate the discovery of new drug therapies to prevent, slow, stop and cure Parkinson's Disease.

This resulted in the formation of the Catalyst Programme velocity (CPv) which operates under the Shake It Up Australia Foundation.

Several years ago key scientists from Cure Parkinson's in the United Kingdom created the Linked Clinical Trials (LCT) study group, which screens and ranks new and promising drug candidates for the treatment of Parkinson's. Shake It Up has been a participant in this process for several years. CPv is focused on five new drug therapies drawn from the LCT process which have been previously identified as having high potential to make a difference to patients with the disease.







Whilst CPv is an Australian initiative we are working closely with The Michael J. Fox Foundation and Cure Parkinsons to ensure international collaboration in the programme.

Success will be measured by the fast tracking of important new therapies that prevent, slow, stop and ultimately cure Parkinson's through phase 1-2-3 trials & these would also become available for patients worldwide.

# WHAT IS PARKINSON'S DISEASE?

Parkinson's disease is a progressive, degenerative neurological condition caused by a loss of dopamine cells in the brain that affects a person's control of their body movements. The disease progresses relentlessly and once dopamine cells are destroyed, the body's mechanical functions are irreversibly damaged. Parkinson's is often challenging to diagnose as there are so many motor symptoms and non-motor symptoms that vary from patient to patient.

## Motor Symptoms

-  Tremor
-  Slowed Movement
-  Rigid Muscles
-  Walking
-  Gait & Balance Problems
-  Frozen Facial Expression

## Non-Motor Symptoms

-  Sleep Disturbance
-  Constipation
-  Depression & Anxiety
-  Loss of Sense of Smell
-  Cognitive Impairment
-  Speech Problems
-  Difficulty Swallowing
-  Vision Problems
-  Apathy & Fatigue


## Parkinson's Statistics in Australia

**100,000** 


Australian's are living with Parkinson's

**2<sup>nd</sup>**

Most common neurological disease in Australia after dementia

**38** 

Australians are diagnosed with Parkinson's every day

**20%** 

of people with Parkinson's are of working age

**PARKINSON'S COST THE ECONOMY**

**\$3 Billion**

annually and the healthcare system \$600 million each year

Without a medical breakthrough the number of Australians with Parkinson's will **DOUBLE** every **15 YEARS**



# LET'S TALK ABOUT PARKINSON'S DISEASE



## Did you know?

38 Australians are diagnosed with Parkinson's every day!  
**That's 1.6 Australians diagnosed per hour!**



## Parkinson's fact:

Men are **1.5 times** more likely to be diagnosed with Parkinson's than women



## Globally

**10 million** individuals are diagnosed with Parkinson's worldwide



## Diagnosis

Parkinson's is difficult to diagnose and there is no specific test for it as symptoms vary between individuals, thereby leading to occasional misdiagnosis.



## Prevalence

It is estimated that in Australia, **100,000** people are living with Parkinson's.

## Shake It Up Australia Foundation

We are a not-for-profit organisation that promotes and funds Parkinson's disease research in Australia to help find better treatments to prevent, slow, stop and cure Parkinson's.

For more information, visit [shakeitup.org.au/understanding-parkinsons](https://shakeitup.org.au/understanding-parkinsons)



## PARTNERSHIPS • THE MICHAEL J. FOX FOUNDATION

Ten years ago the Shake It Up Australia Foundation established a partnership with The Michael J. Fox Foundation for Parkinson's Research (MJFF) to leverage Parkinson's drug development expertise in Australia. This partnership has now invested over \$22 million in Australian Parkinson's research and both MJFF and Shake It Up are committed to raising funds to accelerate research to support the development of new drug therapies to prevent, slow, stop and cure Parkinson's.

A better understanding of Parkinson's genetics is providing researchers with more information and clinical trials in the US are taking a precision-medicine approach, recruiting participants based on individual biology. Therapies to date have not been able to slow or stop disease progression but research funded by MJFF in the following areas is showing promise.

- GBA mutations are the most common genetic cause of Parkinson's disease (PD) yet discovered, accounting for up to 15 percent of all Parkinson's cases, depending on ethnicity. Counteracting the dysfunction associated with GBA mutations – lowered activity of the glucocerebrosidase (GCase) protein – could slow or stop progression of PD.
- The genetic target LRRK2 has been the focus of intense investigation by PD researchers since its discovery in 2004. The first in-human trials of LRRK2 inhibitors started in 2017. Work is ongoing to provide insight into unknown aspects of LRRK2 biology and better target experimental therapies against it.
- A universal feature of Parkinson's is the clumping of the protein alpha-synuclein in the brains and body cells of people with the disease. Multiple drug companies are conducting clinical trials to try to prevent or break up synuclein clumps, which scientists believe could stop PD in its tracks.
- Several potentially disease-modifying therapies continue to advance via “repurposing” – scientifically evaluating drugs approved for various conditions for their benefit in PD.
- The MJFF sponsored Parkinson's Progression Markers Initiative has built the largest dataset and biosample library in the history of PD research. This resource will be invaluable as more people with PD participate in clinical trials. Objective disease tests would speed drug development by identifying people most likely to respond to treatment, tracking disease progression and assessing therapeutic impact.

“When the Foundation started in 2000, we set out to change the game on how Parkinson's research gets done. Two decades later, I'm proud that we have continued to meet this challenge and have become more than just a research organization, but a space where patients bring their wisdom and energy. PPMI's expansion is about getting this done, curing Parkinson's, boiling down to a biomarker that we can identify early on and prevent the disease from ever impacting another family.” - **Michael J. Fox**



Glenda Halliday

## ROBERT A. PRITZKER PRIZE FOR LEADERSHIP IN PARKINSON'S

In October The Michael J. Fox Foundation awarded the 2021 Robert A. Pritzker Prize for Leadership in Parkinson's Research to Professor Glenda Halliday, PhD, Australian National Health and Medical Research Council Leadership Fellow from the University of Sydney.

This award recognises scientists who have made it their life's work to speed better treatments for Parkinson's patients. Professor Halliday's wide-ranging research interests include understanding the broader pathological changes in Parkinson's disease (PD), its progression and the factors that account for the variability of the disease. Her work has led to significant findings implicating cellular pathways and processes in PD. These insights are forging innovative new research initiatives that are guiding research internationally looking at ways to slow, stop and prevent disease progression.

"The work of our Foundation cannot be achieved without the dedication and expertise from the field of Parkinson's researchers leading us to new discoveries and opportunities," said MJFF CEO and Co-Founder Deborah W. Brooks. "Professor Halliday's instrumental research in studying the complexities of Parkinson's biology is bringing us closer to the advancements and treatments we need for people and families living with Parkinson's."

Shake It Up Australia Foundation congratulates **Professor Halliday** for this outstanding and well deserved achievement.

# 2021

## FUNDED RESEARCH PROJECTS

### Project

Targeting the body's circadian clock to improve sleep quality in Parkinson's disease

### Institution

University of Queensland

### Duration

2 years

### Researchers

Oliver Rawashdeh, PhD, Dr. Richard Gordon

### Rationale

Chronic sleep disruption is among the most frequently reported and disabling pathological features of Parkinson's disease. This loss of sleep quality is driven by dysregulation of the body's daily circadian rhythms. Working with Biogen, researchers will evaluate a novel therapeutic tool that targets a core component involved in controlling the activity of the body's biological clock. This component, a protein called CK1, plays a key role in regulating sleep and has been extensively characterized using pharmacological inhibitors – drugs that have been shown to rapidly restore disrupted sleep patterns.



Dr. Oliver Rawashdeh



Dr. Richard Gordon



## 2021 FUNDED RESEARCH PROJECTS

### Project

Validating a novel glycolipid receptor as a disease-modifying therapeutic target for Parkinson's disease

### Institution

University of Queensland

### Duration

18 months

### Researchers

Dr. Richard Gordon, Dr. Rebecca Coll and Dr. Nanthini Jayabalan

### Rationale

In Parkinson's disease immune cells in the brain, gut and blood become persistently activated due to the accumulation of synuclein aggregates and other mechanisms, which can trigger inflammation. Ongoing inflammation is accompanied by changes in the gut microbiome of people with Parkinson's. Both these processes have been shown to contribute to the gradual death of dopamine-producing cells in the brain. Therefore, halting the cycle of inflammation, microbiome dysfunction and brain cell death is considered a promising means by which to slow or stop disease progression.

Previous research at UQ has uncovered that the levels of a key gut microbiome-sensing receptor are elevated in people with Parkinson's disease and in animal models. The research team believe that this signaling pathway could play an important role in regulating persistent inflammation, activation of inflammasomes and early gut dysbiosis in Parkinson's.

They will use a combination of studies in Parkinson's patient samples, animal models and cultured cells to better understand the role of this pathway in the disease. They will also test if mice lacking this receptor progress faster or slower in Parkinson's models.

Results from this project will provide new insights into the underlying mechanisms involved in Parkinson's disease. More importantly, these results could provide a new approach to develop more effective treatments to slow or halt disease progression.





## 2021 FUNDED RESEARCH PROJECTS

### Project

Validating the functional role of the pathogenic microbiome metabolite Trimethylamine (TMA) at the gut-brain axis in Parkinson's disease

### Institution

University of Queensland

### Duration

18 months

### Researchers

Dr. Richard Gordon

### Rationale

Gut dysfunction and microbiome dysbiosis have been linked to the onset and progression of Parkinson's pathology. However, the mechanisms by which an altered gut microbial population can initiate or contribute to disease progression remains poorly defined. The research team recently uncovered that the microbial pathways for synthesis of Trimethylamine (TMA) are specifically elevated in PD patients. Their previous studies in Australian PD patients and other published reports have shown that TMAO is elevated in PD patient bloods and biofluids. Some studies suggest that elevated TMAO levels in PD patients could indicate faster disease progression and associated outcomes. This project aims to define the precise mechanisms by which TMAO can drive Parkinson's disease progression.

The research team will use a combination of animal models to assess if elevated TMAO can exacerbate motor and non-motor symptom features relevant to PD. The results from studies will provide new insights and clear evidence for TMAO as a possible driver of disease progression at the gut-brain axis.



### Project

Development of an anti-inflammatory drug for the treatment of Parkinson's disease

### Institution

UniQuest Pty Ltd

### Duration

12 months

### Researchers

Dr. Brian Dymock & Dr. Richard Gordon

### Rationale

Persistent activation of the immune cells that reside in the brain leads to a state of chronic inflammation that contributes to the degeneration of neurons in Parkinson's disease (PD). The research team have identified a novel inflammatory target in the brain and designed a novel and selective inhibitor that enters the brain to reduce neuroinflammation and neurodegeneration.

This study aims to validate the efficacy of the anti-inflammatory preclinical candidate drug in preclinical models of PD. Initial experiments will apply the novel anti-inflammatory compound to human and mouse inflammatory cells to determine the dose required to inhibit inflammation. The ability of the anti-inflammatory drug candidate to reduce inflammation in the brain will then be determined in two preclinical models of PD. Assuming reduced brain inflammation is observed in these models the effects on PD-related motor performance will be investigated in a long-term preclinical model of the disease.

Therapy with an anti-inflammatory drug will provide a unique, neuroprotective, disease-modifying approach for the treatment of PD.



Dr. Brian Dymock

## Project

Electrophysiological modulators to protect neurons in Parkinson's disease

## Institution

Flinders University

## Duration

3 years

## Researchers

Associate Professor Cedric Bardy PhD

## Rationale

PD symptoms arise when there is loss of >70% of dopaminergic neurons in the substantia nigra. This cell loss increases the electrophysiological stress on the ~30% remaining cells, which have to compensate to maintain midbrain functions. The research team hypothesize that this chronic overload of action potential firing depletes cells of the energy required for other processes (e.g., autophagy or molecular repair). This creates a vicious cycle that perpetuates neurodegeneration and accelerates disease progression.

Restoring mitochondrial pathways and cellular repair functions is an emerging research priority for neuronal protection in Parkinson's but the influence of chronic electrical activity overload on these pathways is poorly understood. For the first time, researchers will reveal the precise mechanisms underlying the vulnerability of patient-derived midbrain neurons to electrical activity overload. In addition, the team will evaluate the potential of established and novel ion channel modulators (ICM) derived from natural peptides to prevent midbrain neuron chronic metabolic exhaustion and death.

This study hopes to predict that periodic ICM treatment can halt the vicious cycle perpetuating neurodegeneration in PD. This innovative project will open the way for a new therapeutic pipeline using electro-pharmacotherapies to slow Parkinson's disease progression.



Cedric Bardy



## 2021 FUNDED RESEARCH PROJECTS

### Project

Australian Parkinson's Genetics Study (APGS)

### Institution

QIMR Berghofer Medical Research Institute

### Duration

2 years

### Researchers

Professor Nick Martin & Dr Miguel E. Rentería.

### Rationale

The Global Parkinson's Genetics Program (GP2) will genotype 150,000 volunteers around the world to further understand the genetic architecture of Parkinson's disease. There is still much to learn about genetic risk factors and the path to further understanding requires working collaboratively and openly sharing data, processes, and results. The Australian Parkinson's Genetics Study (APGS) aims to make a significant and impactful contribution to GP2.

The etiology of Parkinson's is complex, with genetic and environmental risk factors contributing to differences in individual susceptibility and progression. For example, age, mood disorders, head injury, and exposure to environmental toxins have been consistently associated with increased PD risk, and mutations in genes such as LRRK2, PINK1, PARK7, and SNCA are linked with familial forms of PD. Genome-wide association studies of idiopathic Parkinson's have so far identified 90 genomic loci associated with increased risk. However, individually and combined, these loci only explained a small proportion of variance in risk, suggesting there are still hundreds of other genetic risk variants that are yet to be found. Based on experience from genetic studies of other diseases, increasing the number and genetic diversity of both cases and controls in the study are proven ways to increase the number of significant loci and characterise the genetic architecture of the disease.

The research team will recruit 6,000 Australian residents who have been diagnosed with, and medically treated for, Parkinson's disease and analyse their DNA from saliva samples to pinpoint specific genes associated with Parkinson's disease. Researchers will investigate the differences and similarities in these DNA samples to gain a better understanding of why some people develop Parkinson's and others do not. This data will be valuable in developing precision medicine treatments for people with Parkinson's in the future.

## Project

Sitala

## Researchers

Professor Matt Cooper

## Rationale

Sitala is a biotech company driving translational research into new therapies that will block harmful inflammation to help people living with Parkinson's disease. Sitala was founded by Professor Matt Cooper, the co-founder of Inflazome which was sold to Roche in September 2020 for AUS \$620 million. Shake It Up and The Michael J. Fox Foundation were early funders of Professor Cooper's Inflazome research at the University of Queensland.

Shake It Up has funded significant research in Australia on the harmful effect chronic inflammation has on the brain in people living with Parkinson's. Dysfunction of immune cells such as microglia and astrocytes in the brain leads to the production of inflammatory molecules. These stop immune cells from clearing toxins in the brain and accelerate neurodegeneration.

Shake It Up has chosen to become an early investor in Sitala rather than a donor as we feel confident that Professor Cooper's research will make significant progress in delivering improved treatments to slow and stop disease progression in Parkinson's and other neurodegenerative diseases like Alzheimer's. This strategy will ensure that any return on this investment will be reinvested into further cutting-edge Australian Parkinson's research in the future.



Matthew Cooper



## Project

Elucidating cell type-specific PINK1 and PRKN expression in vivo

## Institution

University of Sydney

## Duration

18 months


## Researchers

Professor Deniz Kirik, MD, PhD

## Rationale

PINK1 and Parkin (PRKN) proteins are both involved in mitochondrial quality control, and loss-of-function mutations causing familial forms of PD with earlier onset of symptoms compared to sporadic Parkinson's disease. This study aims to profile PRKN and PINK1 gene and protein expression, PRKN translation, and pS65-Ub levels in vivo in a cell type-focused manner, including phenotypic characterization of the brain cells to address current key knowledge gaps of expression patterns for PRKN and PINK1.

The research team hopes to improve their comprehensive understanding of PRKN/PINK1 function, and to better define the appropriate brain cell types for assessment of novel PRKN/PINK1 animal models and therapeutics.



Deniz Kirik



## 2021 FUNDED RESEARCH PROJECTS

### Project

Confirming the trans-effect in PD gene regulation

### Institution

Garvan Institute of Medical Research

### Duration

3 years

### Researchers

Associate Professor Antony Cooper

### Rationale

Working in collaboration with the University of Auckland this project builds on previous findings specifically looking at single nucleotide polymorphisms that regulate GBA expression and the set of genes regulated by the 90 recognized PD risk loci. The goal of this study is to functionally validate ~12 hits identified using an informatics approach in human stem cell models.

The two objectives of this study include screening PD associated and GBA SNPs in the KOLF2 cell line in a luciferase assay and confirming that variants modulate their respective target genes.

This study has the potential to identify new targets and pathways that play a role in PD and identify modifiers of GBA expression and function that can be used for patient stratification.



## BEQUEST TO PARKINSON'S RESEARCH **HELP US CREATE A BRIGHTER FUTURE**

---

Having an up-to-date Will is one of the most important things you can do for yourself and your family. Writing a Will also allows you to leave a lasting gift to the Shake It Up Australia Foundation to fund cutting edge Parkinson's research in Australia.

Leaving a gift in your estate to Shake It Up provides a legacy to advance treatments and a cure for Parkinson's. Not only will your gift help the 100,000 Australian's living with Parkinson's it will also help future generations.

We have partnered with Gathered Here to offer you the opportunity to write your Will for free, with unlimited updates of your Will for life. You can nominate your Executors, appoint Guardians for your children, divide your estate, leave specific gifts to loved ones and outline your funeral wishes. It's that easy. Please help us achieve our vision of a world without Parkinson's by leaving a Bequest to Shake It Up in your Will.



# PAUSE 4 PARKINSON'S

## PAUSE 4 PARKINSON'S 2021

For the second year in a row the COVID-19 pandemic significantly hampered our Pause 4 Parkinson's campaign with many community fundraisers unable to participate due to changing restrictions in their local community. Despite that, many of our supporters did fundraise by taking on a personal challenge.

2021 marked our 10th anniversary and we celebrated the IMPACT Shake It Up has had on progress towards better treatments for Parkinson's. Our Patron, His Excellency General the Honourable David Hurley AC DSC (Retd), Governor-General of the Commonwealth of Australia and Mrs Hurley generously hosted a small celebratory event at Admiralty House in March with the Foundation's major donors to commemorate this important occasion.

Shake It Up are committed to building on the momentum in Parkinson's research and pushing ahead towards better treatments that will prevent, slow and stop Parkinson's and ultimately lead to a cure. A big thank you to everyone who participated in Pause 4 Parkinson's this year – we are looking forward to 2022!



# PAUSE 4 PARKINSON'S 2021

## COMMUNITY FUNDRAISING HEROES



### Lyle Hammerschlag – 10km Challenge

Lyle, and his friends and family, completed 40 laps of Camp Cove for Parkinson's and raised \$15k for Shake It Up. They were our Pause 4 Parkinson's 2021 highest fundraisers and Lyle swam the 10km challenge for his Uncle who has Parkinson's.



### David Cox's Coastal Walk

David and his team walked over 42kms in 10 hours from Bondi to Manly this year raising over \$7,242 and much awareness about Parkinson's. David also tested the new Walking Tall Health device which uses peripheral neuronal stimulation embedded in smart socks to help people with Parkinson's walk.



### Annie Hick's Walk for Parkinson's

Together with her friends and family, Annie completed a 20km walk and raised \$8,704 for Shake It Up to speed a cure for Parkinson's.



### Paws 4 Parkinson's

Paws 4 Parkinson's returned for 2021 with the help of volunteers from the University of Sydney's Poke Initiative. The Poke Initiative volunteers specialise in social media and helped this campaign to reach a greater audience through a competition for Shake It Up's first ever Pet Ambassador, decided by popular vote and won by Lola the Beagle.

# COMMUNITY FUNDRAISING



Many of our supporters worked tirelessly to navigate restrictions and fundraise for Parkinson's and while many of our traditional community events like high teas and luncheons were cancelled, personal challenges increased. We had individuals walk, run, swim, and cycle tens of thousands of kilometres for Shake It Up!

Unfortunately, our Inspired Adventures trek to Bay of Fires in Tasmania was postponed until September 2022 due to COVID-19 restrictions. However, many participants were still motivated to reach out to their networks, raising \$41,250 this year for Parkinson's Research.

We thank our community fundraisers for their unwavering support as we continue to navigate our way through the COVID-19 pandemic.

## MATES RIDE ACROSS AUSTRALIA FOR PARKINSONS



Long-time Shake It Up supporters, the Monkey Mia boys, have been fundraising through desert rides across Australia since 2018. The group of eight friends earned the nickname 'Monkey Mia boys' from their first fundraising ride which stretched from the Western most point of Australia (Monkey Mia) to the Eastern most point (Byron Bay). Since then, they have completed three other trips; one along the Canning Stock Route in 2019, the Covid-19 Desert Challenge in 2020 and the Simpson Desert in 2021.

The group was inspired to take on this huge desert adventure challenge to raise funds for Shake It Up as two of the group, retired farmers Noel Passalaqua and Andrew Urquhart, have Parkinson's. Together, over the four years the crew have raised a huge \$185,220 for Shake It Up to further research and spread awareness about Parkinson's throughout rural communities along their travels. A big shout out to the Monkey Mia team for their support.

Noel Passalaqua, Andrew Urquhart, Jim Salter, Phil Davies, Tom Ellis, Harry Chisolm, David Cato and Tom Manifold.

# OUR HEROES



## Tribute Boxing 20,000km Challenge

A huge team of over 140 people from Tribute Boxing, led by Alex and Leo, recently worked together to walk, run, cycle and swim over 30,000km for Parkinson's. The team were inspired to challenge themselves during lockdown to stay active and motivated while fundraising for a cause close to their heart. Together they raised \$12,693.



## Point to Pinnacle

This year for the Point to Pinnacle, we had our largest group of participants yet, thanks to our regular group of Olivia Bailey and her family and friends and a new group led by Sonya Enkelmann supporting Young Onset Parkinson's. Altogether, they have raised \$10,410.



## Shake Off Face Off

In May ice skaters Owen and Sandra Turner, along with their daughters Mikaela and Kiera and Kiera's partner Elijah challenged themselves to skate the same distance as a National Hockey League player skates in an entire season, that's 660km in 3 months! Together, the team completed their challenge and raised \$5,950 for Parkinson's research.



## Everest on Mt Coolum

Gary and his team of Everest Trekkers recently completed their trekking challenge – to walk the same distance as Everest from wherever they are in Australia. Most of the group are from QLD and completed the trek together on Mt Coolum, ascending the mountain 42 times over a week. Over the three years that Gary has hosted an Everest Trek his teams have collectively raised \$20,269 for Parkinson's research.



## Suzanne Runs 45km Bush Trail for Parkinson's

Last year, Suzanne ran 130km in 14 days – the same distance as Everest in the same time it took her late father who had Parkinson's to complete the Everest Base Camp walk, raising \$11,933.

For 2021, Suzanne decided to complete the same Blue Mountains Ultra Marathon trail her father had completed when he was 56. It was a grueling effort but Suzanne raised a further \$6,004 to bring her total fundraising tally to \$17,937 – Congratulations Suzanne!



## Tom Does 10,000 Pushups for Parkinson's

Motivated by his Mum who has Parkinson's, Tom took on a monumental challenge to complete 10,000 push ups for Parkinson's. Tom successfully completed his challenge and raised \$5,255 for Parkinson's research.



## Will & Corrie Boag Continue Their Walking Odyssey

Long-time Shake It Up supporters, Will and Corrie Boag, continued their walking adventures this year for Shake It Up, this time heading to the Adelaide Hills and Flinders Ranges. Will and Corrie have previously supported Shake It Up through walks in countries all over the world – Portugal, France, Switzerland, Italy, Spain and Australia. Over the years they have been walking, they have raised \$19,556 for Parkinson's.




















## Mimi Shaves Her Head for Parkinson's

Mimi bravely fundraised for Shake It Up while preparing for DBS surgery. Mimi collected funds in the lead up to shaving her head for the treatment. With the help of her generous friends and family, Mimi raised \$4,389 for Parkinson's research.

# CORPORATE SUPPORT

Volunteer and pro bono support are invaluable in extending our reach to increase awareness and donations to the foundation. We are grateful to the following companies for their financial and pro bono support in 2021.

	Noel Holmes Group		The Daily Press		Telum
	Insurance Advisernet		Novotech		HelloEd
	MediRecords		Metro Rehab		Royal Rehab Private
	Reliant Healthcare		Hutchinson Builders		Canyon
	Ooh! Media		Pharmacy Club		Veritas
	PWC		Walter Wakefield		Alex Byrne
					Sarah Chavdaroska

## Sohn Hearts & Minds Investment Leaders Conference

The annual Sohn Hearts & Minds Investment Leaders Conference brings the investment community together to raise funds for medical research. Shake It Up was again a beneficiary of a \$100,000 donation from this year's conference. We thank the Sohn Hearts & Minds team for their ongoing support and for their vision of supporting Australian medical research through this innovative event.

# GET INVOLVED

Can you **Pledge** or **Participate** to help us fund cutting edge Australian Parkinson's research in our pursuit of a cure?

## PLEDGE

Funding cutting edge research is a long-term commitment and requires significant investment. We need your help to ensure we can continue to accelerate research in Australia to achieve our mission of discovering new therapies to prevent, slow, stop and cure Parkinson's disease.

### Donate

Visit our website to make a one-off donation to fund Parkinson's research. 100% of every donation is directed to Parkinson's research in Australia which is made possible by our founding directors who cover all administration costs of the foundation. <https://shakeitup.org.au/donate/>

### Workplace and Regular Giving

Support us by making a regular monthly donation to help us plan ahead and commit to world leading Parkinson's research. You can do this through your workplace and employers will often match your donation. Or sign up on our website to become a regular giver and join our Movers & Shakers Club.

## PARTICIPATE

### Take on a Challenge

Challenge yourself for Parkinson's! Walk, cycle, run, swim, climb, it's your choice. Choose your favourite activity and set yourself a challenge and get your family, friends and work colleagues to donate to help you achieve your goal. It's that easy.

<https://shakeitup.org.au/get-involved/physical-challenges/>

### Join an Event

Every month of the year all around Australia there are fundraising events you can join and nominate Shake It Up as your charity beneficiary. Visit <https://shakeitup.org.au/get-involved/join-an-athletic-event/> to check out events near you.

### Organise your own event

Not into physical challenges, no problem! You can organise a morning tea, a trivia night, a wine and cheese tasting, bbq or whatever takes your fancy. Gather your friends together and fundraise for Parkinson's research. <https://shakeitup.org.au/get-involved/fundraise-for-parkinsons/>

# OUR AMBASSADORS

Shake It Up is honoured to have the support of a number of high-profile Australians who help us to increase community awareness about Parkinson's and raise funds for research. They give generously of their time each year and we thank them for their service.



## Bloom

"I feel fortunate to be in a position with my work to be able to raise awareness and funds for Australians with Parkinson's. Our Bloomies are so generous, to date we have raised \$19,590.30 for Shake It Up Australia. There is not one show that I do, that I don't meet someone that hasn't personally been affected by Parkinson's"



## Peter Byrne

"Making a career out of being a performer and entertainer over 30 years has given me so much joy thanks to the music of Neil Diamond. His Parkinson's diagnosis inspired me to want to give back and spread the word as much as I could. I am a proud Ambassador for Shake it Up and in the words of one of his songs, I will always be "reaching out, touching me and touching you" in my fight to create awareness and raise funds for this terrible disease."



## Craig Foster AM

"I am thrilled to be an Ambassador for Shake It Up. Parkinson's impacts older and younger people alike. A world without Parkinson's is an ambitious vision. The work that Clyde Campbell, the team at Shake It Up and researchers are doing to find a cure and improve the lives of those with Parkinson's is truly remarkable."



## Liz Cantor

"Being an ambassador for Shake It Up is on a personal note, a nod to my Grandma, a professional ballerina who lost control of her body, and on a larger scale my way of acknowledging the momentum that is going into finding a cure for Parkinson's disease."



## Lincoln Dews

"Being a Shake It Up Ambassador is a tremendous honour. Having seen the effects of Parkinson's disease firsthand I'm forever grateful of the work Shake It Up continues to do."



## Phobes Garland

"I am passionate about taking the stigma out of Parkinson's disease and having a voice for those that are still coming to terms with their diagnosis, so they feel no shame living with this disease."

*"I hope being an Ambassador allows an open conversation for people who are suffering from this and creates awareness so we can get better treatments that leads to slowing and stopping the disease in its tracks."*



## Kate Stone Matheson

"Being a Shake it Up Ambassador allows me to show how someone who actually has the disease can continue to grow, educate and be educated about Young Onset Parkinson's. Clyde, and the Board's vision for unified research is positively impacting everyone within the Parkinson's world - not just those living with the disease, but those who help them live it. I feel enormously thankful and proud to be part of the Shake It Up team!"



## Kristy Johnson

"I'm so proud to be in the company of other Shake It Up ambassadors, who use their profile and first-hand experience of living with Parkinson's Disease to raise awareness. Looking forward to 2022."



## Desperado –The Eagles Show

"There are two questions that are frequently asked at our shows, one is have I been playing music all my life, to which I answer, "not yet" and the second question is how am I feeling, to which I answer "better than I should be"... Music will cure things that medicines never will, so to be part of the Desperado show has been a lifeline for myself. When I heard about Shake It Up, I put it to the guys and their response was unanimous and by using Facebook as a platform we are able to spread the word and awareness plus raise a little bit of money along the way, all thanks to the Shake It Up Foundation... So very proud to be Ambassadors for this amazing foundation." Vernon Aliberti

# TEAM SHAKE IT UP

Ten years on the Shake It Up Australia Foundation has remained true to its original business model of directing 100% of all funds raised to Parkinson's research in Australia. This is made possible by the founding directors who continue to cover all administration costs of the foundation. The Shake It Up team remains small but mighty in steering the Foundation to achieve its Mission and Vision.



**Clyde Campbell**  
Founder & CEO



**Vicki Miller**  
Executive General Manager,  
Strategic Partnerships



**Carolyn Campbell**  
Operations Manager



**Isobel Moore**  
Community Fundraising  
& Events Manager

“Mighty things from small beginnings grow.”  
- **John Dryden.**



# OUR BOARD

Shake It Up values the professional expertise of our Board who give so generously of their time. The Board meets ten times each year to oversee the strategic direction of the foundation, monitor performance and risk and ensure good governance practices are implemented and maintained.



**Clyde Campbell**



**Graeme Fear**



**Greg Campbell**



**Rick Crethar**



**Tony Dormer**



**Jenny Hosie**



**Noel Holmes**



**Andrew Mulcahy**



**Ben Young**



**Katrina Hodgkinson**

Shake It Up is a registered charity under the Australian Charities and Not-For-Profits Commission.



# ANNUAL FINANCIAL SUMMARY

## Shake It Up Australia Foundation

**Shake It Up Australia Foundation Trust** ABN 65 270 391 304  
**Shake It Up Australia Foundation Charitable Trust** ABN 21 285 919 076  
Combined Summary Financial Statement Ended June 2021

Income Donations	\$2,231,285
<b>Total Income</b>	<b>\$2,231,285</b>
Grants Funded	\$1,265,339
Administration Expenses*	\$304,625
<b>Net Surplus (Deficit)</b>	<b>\$661,321</b>
Total Assets	\$5,432,632
Current Liabilities	\$18,885
Research Projects Funding Committed	\$1,172,769
<b>Net Assets</b>	<b>\$4,240,978</b>

\*Note: 100% of all Administration Expenses are covered by our founding directors.  
Full 2020-2021 Financial information is available on our website or the ACNC.



“

# ACCEPTANCE DOESN'T MEAN RESIGNATION!

Michael J. Fox

**#DOIT4PARKINSONS**



